Market Cap
US$233.1m
Last Updated
2021/01/22 00:31 UTC
Data Sources
Company Financials +
Executive Summary
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Limited growth with imperfect balance sheet.
Similar Companies
Share Price & News
How has Sientra's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SIEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SIEN's weekly volatility has decreased from 18% to 10% over the past year.
Market Performance
7 Day Return
0.4%
SIEN
0.9%
US Medical Equipment
1.4%
US Market
1 Year Return
-32.8%
SIEN
20.4%
US Medical Equipment
22.6%
US Market
Return vs Industry: SIEN underperformed the US Medical Equipment industry which returned 20.2% over the past year.
Return vs Market: SIEN underperformed the US Market which returned 22.8% over the past year.
Shareholder returns
| SIEN | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | 0.9% | 1.4% |
| 30 Day | 15.8% | 4.1% | 4.9% |
| 90 Day | 0% | 7.8% | 14.6% |
| 1 Year | -32.8%-32.8% | 21.4%20.4% | 25.4%22.6% |
| 3 Year | -64.0%-64.0% | 67.0%62.8% | 46.8%37.0% |
| 5 Year | -42.8%-42.8% | 175.6%155.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is Sientra's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Here's What Sientra, Inc.'s (NASDAQ:SIEN) Shareholder Ownership Structure Looks Like1 month ago | Simply Wall St
Sientra (NASDAQ:SIEN) Is Making Moderate Use Of Debt2 months ago | Simply Wall St
Sientra, Inc. (NASDAQ:SIEN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.50Valuation
Is Sientra undervalued compared to its fair value and its price relative to the market?
12.88x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SIEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SIEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SIEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SIEN is overvalued based on its PB Ratio (12.9x) compared to the US Medical Equipment industry average (5.4x).
Next Steps
Future Growth
How is Sientra forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
27.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SIEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SIEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SIEN's revenue (22.6% per year) is forecast to grow faster than the US market (10.5% per year).
High Growth Revenue: SIEN's revenue (22.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SIEN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Sientra performed over the past 5 years?
-22.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SIEN is currently unprofitable.
Growing Profit Margin: SIEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SIEN is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare SIEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SIEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: SIEN has a negative Return on Equity (-491.91%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sientra's financial position?
Financial Position Analysis
Short Term Liabilities: SIEN's short term assets ($137.7M) exceed its short term liabilities ($57.2M).
Long Term Liabilities: SIEN's short term assets ($137.7M) exceed its long term liabilities ($102.5M).
Debt to Equity History and Analysis
Debt Level: SIEN's debt to equity ratio (355.3%) is considered high.
Reducing Debt: SIEN's debt to equity ratio has increased from 16.9% to 355.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SIEN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SIEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.6% each year
Next Steps
Dividend
What is Sientra current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SIEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SIEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SIEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SIEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SIEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Ron Menezes
0.17
Tenure
Mr. Ron Menezes serves as President and Chief Executive Officer of Sientra, Inc. since November 10, 2020. Mr. Menezes served as President and General Manager at Almirall, LLC since August 23, 2017. Mr. Men...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO, Senior VP & Treasurer | 2.42yrs | US$958.60k | 0.10% $ 235.4k | |
| Consultant | 1.33yrs | US$1.00m | no data | |
| Director & Advisor to MiraDry Business | 3.42yrs | US$521.60k | 0.44% $ 1.0m | |
| Executive Chair of Board of Directors | 0.17yr | no data | no data | |
| President & CEO | 0.17yr | no data | no data | |
| Vice President of Operations | no data | no data | no data | |
| Vice President of Human Resources & Corporate Administration | no data | no data | no data | |
| General Counsel and VP of Compliance & Legal | 3yrs | no data | 0.15% $ 343.7k | |
| Senior Vice President of Worldwide Sales | 0.92yr | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| VP & Corporate Controller | 2.83yrs | no data | no data |
1.9yrs
Average Tenure
55.5yo
Average Age
Experienced Management: SIEN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director & Advisor to MiraDry Business | 3.42yrs | US$521.60k | 0.44% $ 1.0m | |
| Executive Chair of Board of Directors | 0.17yr | no data | no data | |
| Lead Independent Director | 5.17yrs | US$210.00k | 0.11% $ 263.3k | |
| Independent Director | 6.5yrs | US$190.00k | 0.14% $ 337.6k | |
| Independent Director | 2yrs | US$334.18k | 0.046% $ 107.6k | |
| Independent Director | 3.92yrs | US$302.50k | 0.13% $ 291.7k |
3.7yrs
Average Tenure
60yo
Average Age
Experienced Board: SIEN's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sientra, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sientra, Inc.
- Ticker: SIEN
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$233.098m
- Shares outstanding: 50.45m
- Website: https://sientra.com
Number of Employees
Location
- Sientra, Inc.
- 420 South Fairview Avenue
- Suite 200
- Santa Barbara
- California
- 93117
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SIEN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 2014 |
| S0Z | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2014 |
Biography
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The comp...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 00:31 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.